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antidepressant,[22] anticonvulsant,[23] and antiviral[24] 
activities. The aim of the present work was to attach 
pyrazoline molecule to quinazolin-4(3H)one in order 
to find new biologically active pharmacophore. Thus, 
synthesis of pyrazolyl-quinazolin-4(3H)ones 6a-m has been 
achieved. The potency[25] of compounds 6a-m is compared 
with standard drugs to study the strength of compounds 
6a-m, with a hope to get a better antimicrobial agent.
MATERIALS AND METHODS
The melting points were determined in open capillary 
tubes and are uncorrected. The infrared (IR) spectra of the 
synthesized compounds were recorded using KBr pellet 
on Perkin Elmer 1300 FTIR spectrometer and frequencies 
INTRODUCTION
The recent literature reveals that the quinazolinone moiety 
associated with various aromatic as well heterocyclic 
compounds possess wide range of pharmacological 
properties such as antibacterial,[1] antifungal,[1] analgesic,[2] 
anti-inflammatory,[3] anthelminthic,[4] anticonvulsant,[5] anti 
HIV,[6] antitubercular,[7] CNS depressant,[8] cytotoxicity,[9] 
diuretic,[10] and hypolipidemic[11] activities. Pyrazoline 
systems are known to be biologically active and are 
important constituents of many pharmacological products. 
These compounds are known for their antibacterial,[12] 
antifungal,[13]  antimycobacterial,[14]  analgesic,[15] 
anti-inflammatory,[16] anticancer,[17] antiamoebic,[18] 
molluscicidal,[19] hypotensive,[20] antinociceptive,[21] 
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ABSTRACT
A series of 2-[2-(2,6-dichlorophenyl)amino]benzyl-3-(5-substituted phenyl-4,5-dihydro-1H-pyrazol-3-yl-amino)-
6,8-dibromoquinazolin-4(3H) ones 6a-m have been synthesized by the reaction of  2-[2-(2,6-dichlorophenyl)
amino]benzyl-3-substituted phenylacrylamido-6,8-dibromoquinazolin-4(3H) ones 5a-m with hydrazine 
hydrate in the presence of glacial acetic acid. The chalcones 5a-m were prepared by the condensation of 
2-[2-(2,6-dichlorophenyl)amino]benzyl-3-acetamido-6,8-dibromoquinazolin-4(3H)one 4 with different substituted 
aromatic aldehyde. The benzoxazinone 2 was synthesized from 2-[2-(2,6-dichlorophenyl)amino]phenyl acetyl 
chloride 1 on treatment with 3,5-dibromoanthranilic acid in pyridine, which on reaction with hydrazine hydrate and 
then on acetylation reaction yielded 4. The structures of these compounds have been elucidated by elemental 
analyses, IR, and NMR spectral data. The title compounds pyrazolyl-quinazolin-4(3H)ones 6a-m were evaluated 
for their antibacterial and antifungal activities in vitro.   
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are recorded in wave number (cm-1). Nuclear magnetic 
resonance (1H-NMR and 13C-NMR) spectra were recorded 
on Bruker Avance II 400 NMR spectrometer using 
deutero chloroform (CDCl3) as a solvent. The chemical 
shifts are reported in δ (part per million) downfield from 
tetramethylsilane (TMS) as an internal standard. The purity 
of all the compounds was checked by TLC on Merck silica 
gel 60 F254 using toluene:ethylacetate (8:2) as mobile 
phase, and spots were visualized under UV radiation. 
2-[(2,6-Dichlorophenyl)amino]phenyl acetyl chloride 1 was 
synthesized by the literature procedure.[26]
Procedure for the preparation of 2-[2-(2,6-Dichlorophenyl)
amino]benzyl-6,8-dibromo-3,1-benzoxazin-4(H)one (2)
A mixture of 2-[(2,6-dichlorophenyl)amino]phenyl acetyl 
chloride 1 (0.01 mol) and 3,5-dibromo anthranilic acid (0.01 
mol) in 20 ml pyridine was stirred at 0-5 ºC for 1 h,  further 
stirred for 1 h at room temperature. After completion of 
reaction, a pasty mass obtained and was washed thoroughly 
with sodium bicarbonate (5 % w/v) to remove unreacted 
acid. A solid separated was filtered, dried, and recrystallized 
from methanol.
Yield: 68%. m.p. 171-173 °C. IR (KBr) (cm-1): 3447 (NH 
str), 2927, 2854 (CH2 str), 1748 (C=O str), 1614 (C=N str), 
1150 (C-O str), 743 (C-Cl str), 565 (C-Br str). 1H-NMR 
(CDCl3, 400 MHz), δ (ppm): 3.55 (s, 2H, CH2), 6.37-8.15 
(m, 9H, Ar-H), 9.13 (bs, 1H, NH). Anal. found: C, 45.36; 
H, 2.15; N, 5.07 %; Calcd. for C21H12Br2Cl2N2O2, C, 45.44; 
H, 2.18; N, 5.05 %. 
Procedure for the preparation of 3-Amino-2-[2-(2,6-
dichlorophenyl)amino]benzyl-6,8-dibromoquinazolin-
4(3H)one (3)
A mixture of 2-[2-(2,6-dichlorophenyl)amino]benzyl-
6,8-dibromo-3,1-benzoxazine-4(H)one 2 (0.01 mol) and 
hydrazine hydrate (0.01 mol) in 25 ml absolute ethanol 
was refluxed on water bath for 6-8 h. After completion of 
the reaction, it was slowly poured onto crushed ice with 
continuous stirring. The solid thus obtained, was filtered, 
and washed several times with cold water. The crude 
product was dried and recrystallized from ethanol.    
Yield: 64%. m.p. 146-148 °C. IR (KBr) (cm-1): 3510-3393 
(NH and NH2 str), 2932, 2857 (CH2 str), 1721 (C=O str), 
1612 (C=N str), 748 (C-Cl str), 570 (C-Br str). 1H-NMR 
(CDCl3, 400 MHz), δ (ppm): 3.58 (s, 2H, CH2), 5.75 (bs, 
2H, NH2), 6.38-8.10 (m, 9H, Ar-H), 9.15 (bs, 1H, NH). 
Anal. found: C, 44.25; H, 2.53; N, 9.81 %; Calcd. for 
C21H14Br2Cl2N4O, C, 44.32; H, 2.48; N, 9.85 %. 
Procedure for the preparation of 2-[2-(2,6-Dichlorophenyl)
amino]benzyl-3-acetamido-6,8-dibromoquinazolin-4(3H)
one (4)
To the solution of 3-amino-2-[2-(2,6-dichlorophenyl)
amino]benzyl-6,8-dibromoquinazolin-4(3H)one 3 (0.01 
mol) in 50 ml dry benzene, acetyl chloride (0.01 mol) was 
added drop by drop at 0-5 °C  over the period of 1 h with 
continuous shaking. After completion of the addition, 
the reaction mixture was kept overnight. The excess of 
solvent was distilled off under reduced pressure and then 
poured onto ice and shaken well. The solid thus obtained 
was filtered and recrystallized from methanol.
Yield: 69 %. m.p. 193-195 °C. IR (KBr) (cm-1): 3447 (NH 
str), 2935, 2859 (CH2 str), 1727 (C=O str), 1645(C=O str 
of amide), 1615 (C=N str), 753 (C-Cl str), 573 (C-Br str). 
1H-NMR (CDCl3, 400 MHz), δ (ppm): 2.23 (s, 3H, CH3), 
3.53 (s, 2H, CH2), 6.37-8.12 (m, 9H, Ar-H), 9.14 (bs, 1H, 
NH), 10.32 (bs, 1H, NH). Anal. found: C, 45.28; H, 2.61; 
N, 9.15 %; Calcd. for C23H16Br2Cl2N4O2, C, 45.20; H, 2.64; 
N, 9.17 %. 




To the solution of 2-[2-(2,6-dichlorophenyl)amino]benzyl-
3-acetamido-6,8-dibromoquinazolin-4(3H)one 4 (0.01 
mol) in 50 ml absolute ethanol, benzaldehyde (0.01 mol) 
in 2 % NaOH was added and refluxed for 10-12 h. After 
completed the reaction, it was concentrated, cooled, and 
poured onto ice. The solid thus obtained was filtered, 
washed with water, and recrystallized from methanol. The 




Yield: 67 %. m.p. 146-148 °C. IR (KBr) (cm-1): 3441 (NH 
str), 2921, 2852 (CH2 str), 1719 (C=O str), 1613 (C=N str), 
1576 (CH=CH str), 749 (C-Cl str), 578 (C-Br str). 1H-NMR 
(CDCl3, 400 MHz), δ (ppm): 3.56 (s, 2H, CH2), 6.39-8.16 
(m, 14H, Ar-H), 6.80 (d, 1H, =CHCO, J = 16 Hz), 7.62 
(d, 1H, =CH-Ar, J = 16 Hz), 8.84 (bs, 1H, CONH), 9.18 
(bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.57 
(CH2), 112.37-148.53 (26C, CH=CH and Ar-C), 162.06 
(C=O), 168.25 (C=N), 173.12 (CONH). Anal. found: C, 
51.46; H, 2.92; N, 8.04 %; Calcd. for C30H20Br2Cl2N4O2, C, 
51.53; H, 2.88; N, 8.01%.




Yield: 72%. m.p. 156-158 °C. IR (KBr) (cm-1): 3547 (OH 
str), 3438 (NH str), 2926, 2854 (CH2 str), 1722 (C=O str), 
1617 (C=N str), 1566 (CH=CH str), 757 (C-Cl str), 573 (C-
Br str). 1H-NMR (CDCl3, 400 MHz), δ (ppm): 3.54 (s, 2H, 
CH2), 6.37-8.13 (m, 13H, Ar-H), 6.78 (d, 1H, =CHCO, J = 
16.2 Hz), 7.59 (d, 1H, =CH-Ar, J = 16.2 Hz), 8.82 (bs, 1H, 
CONH), 9.16 (bs, 1H, NH), 10.36 (bs, 1H, OH). 13C-NMR 
(CDCl3, 100 MHz), δ (ppm): 30.63 (CH2), 112.23-155.67 
(26C, CH=CH and Ar-C), 161.82 (C=O), 168.40 (C=N), 
173.22 (CONH). Anal. found: C, 50.35; H, 2.86; N, 7.79 %; 




Yield: 66%. m.p. 171-173 °C. IR (KBr) (cm-1): 3542 (OH 
str), 3450 (NH str), 2930, 2855 (CH2 str), 1726 (C=O str), 
1612 (C=N str), 1575 (CH=CH str), 752 (C-Cl str), 580 (C-
Br str). 1H-NMR (CDCl3, 400 MHz), δ (ppm): 3.51 (s, 2H, 
CH2), 5.57 (bs, 1H, OH), 6.37-8.14 (m, 13H, Ar-H), 6.80 (d, 
1H, =CHCO, J = 16.2 Hz), 7.63 (d, 1H, =CH-Ar, J = 16.2 
Hz), 8.86 (bs, 1H, CONH), 9.15 (bs, 1H, NH). 13C-NMR 
(CDCl3, 100 MHz), δ (ppm): 30.60 (CH2), 112.18-159.29 
(26C, CH=CH and Ar-C), 162.12 (C=O), 168.17 (C=N), 
172.98 (CONH). Anal. found: C, 50.31; H, 2.77; N, 7.88 %; 




Yield: 73 %. m.p. 184-186 °C. IR (KBr) (cm-1): 3548 (OH 
str), 3446 (NH str), 2934, 2853 (CH2 str), 1720 (C=O 
str), 1609 (C=N str), 1572 (CH=CH str), 748 (C-Cl str), 
581 (C-Br str).  1H-NMR (CDCl3, 400 MHz), δ (ppm): 
3.58 (s, 2H, CH2), 5.59 (bs, 1H, OH), 6.38-8.12 (m, 13H, 
Ar-H), 6.81 (d, 1H, =CHCO, J = 16.4 Hz), 7.62 (d, 1H, 
=CH-Ar, J = 16.4 Hz), 8.80 (bs, 1H, CONH), 9.15 (bs, 
1H, NH). 13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.45 
(CH2), 112.23-157.32 (26C, CH=CH and Ar-C), 161.93 
(C=O), 168.03 (C=N), 173.34 (CONH). Anal. found: C, 
50.42; H, 2.83; N, 7.76%; Calcd. for C30H20Br2Cl2N4O3, 




Yield: 72 %. m.p. 145-147 °C. IR (KBr) (cm-1): 3444 (NH 
str), 2922, 2846 (CH2 str), 1723 (C=O str), 1614 (C=N str), 
1578 (CH=CH str), 745 (C-Cl str), 583 (C-Br str). 1H-NMR 
(CDCl3, 400 MHz), δ (ppm): 3.55 (s, 2H, CH2), 6.37-8.13 
(m, 13H, Ar-H), 6.78 (d, 1H, =CHCO, J = 16.4 Hz), 7.61 
(d, 1H, =CH-Ar, J = 16.4 Hz), 8.81 (bs, 1H, CONH), 9.13 
(bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.26 
(CH2), 111.95-148.49 (26C, CH=CH and Ar-C), 162.02 
(C=O), 168.18 (C=N), 173.27 (CONH). Anal. found: C, 
49.20; H, 2.67; N, 7.61 %; Calcd. for C30H19Br2Cl3N4O2, C, 




Yield: 65 %. m.p. 163-165 °C. IR (KBr) (cm-1): 3451 (NH 
str), 2926, 2849 (CH2 str), 1718 (C=O str), 1611 (C=N str), 
1580 (CH=CH str), 755 (C-Cl str), 580 (C-Br str). 1H-NMR 
(CDCl3, 400 MHz), δ (ppm): 3.52 (s, 2H, CH2), 6.38-8.15 
(m, 13H, Ar-H), 6.82 (d, 1H, =CHCO, J = 16.2 Hz), 7.60 
(d, 1H, =CH-Ar, J = 16.2 Hz), 8.79 (bs, 1H, CONH), 9.16 
(bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.42 
(CH2), 112.08-148.36 (26C, CH=CH and Ar-C), 161.87 
(C=O), 167.92 (C=N), 173.14 (CONH). Anal. found: C, 
49.06; H, 2.57; N, 7.68 %; Calcd. for C30H19Br2Cl3N4O2, C, 




Yield: 69 %. m.p. 176-178 °C. IR (KBr) (cm-1): 3447 (NH 
str), 2930, 2855 (CH2 str), 1716 (C=O str), 1610 (C=N str), 
1576 (CH=CH str), 744 (C-Cl str), 571 (C-Br str). 1H-NMR 
(CDCl3, 400 MHz), δ (ppm): 3.58 (s, 2H, CH2), 6.37-8.13 
(m, 13H, Ar-H), 6.84 (d, 1H, =CHCO, J = 16 Hz), 7.60 
(d, 1H, =CH-Ar, J = 16 Hz), 8.82 (bs, 1H, CONH), 9.17 
(bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.55 
(CH2), 112.12-148.59 (26C, CH=CH and Ar-C), 162.14 
(C=O), 167.88 (C=N), 173.03 (CONH). Anal. found: C, 
49.17; H, 2.65; N, 7.58 %; Calcd. for C30H19Br2Cl3N4O2, C, 




Yield: 70%. m.p. 202-204°C. IR (KBr) (cm-1): 3454 (NH 
str), 2932, 2856 (CH2 str), 1723 (C=O str), 1615 (C=N 
str), 1582 (CH=CH str), 1544, 1361 (NO2 str), 745 (C-Cl 
str), 577 (C-Br str). 1H-NMR (CDCl3, 400 MHz), δ (ppm): 
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3.54 (s, 2H, CH2), 6.38-8.16 (m, 13H, Ar-H), 6.83 (d, 1H, 
=CHCO, J = 16.2 Hz), 7.62 (d, 1H, =CH-Ar, J = 16.2 
Hz), 8.81 (bs, 1H, CONH), 9.16 (bs, 1H, NH). 13C-NMR 
(CDCl3, 100 MHz), δ (ppm): 30.38 (CH2), 112.06-150.29 
(26C, CH=CH and Ar-C), 162.25 (C=O), 168.04 (C=N), 
172.91 (CONH). Anal. found: C, 48.36; H, 2.52; N, 9.46%; 




Yield: 68%. m.p. 227-229°C. IR (KBr) (cm-1): 3453 (NH 
str), 2930, 2856 (CH2 str), 1722 (C=O str), 1606 (C=N 
str), 1576 (CH=CH str), 1538, 1356 (NO2 str), 741 (C-
Cl str), 573 (C-Br str).  1H-NMR (CDCl3, 400 MHz), δ 
(ppm): 3.52 (s, 2H, CH2), 6.37-8.40 (m, 13H, Ar-H), 6.82 
(d, 1H, =CHCO, J = 16 Hz), 7.64 (d, 1H, =CH-Ar, J = 16 
Hz), 8.84 (bs, 1H, CONH), 9.15 (bs, 1H, NH). 13C-NMR 
(CDCl3, 100 MHz), δ (ppm): 30.35 (CH2), 112.23-150.44 
(26C, CH=CH and Ar-C), 161.98 (C=O), 168.28 (C=N), 
172.84 (CONH). Anal. found: C, 48.34; H, 2.60; N, 9.43%; 




Yield: 63%. m.p. 238-239°C. IR (KBr) (cm-1): 3446 (NH 
str), 2932, 2857 (CH2 str), 1726 (C=O str), 1608 (C=N 
str), 1585 (CH=CH str), 1543, 1362 (NO2 str), 756 (C-Cl 
str), 582 (C-Br str). 1H-NMR (CDCl3, 400 MHz), δ (ppm): 
3.58 (s, 2H, CH2), 6.38-8.16 (m, 13H, Ar-H), 6.80 (d, 1H, 
=CHCO, J = 16.2 Hz), 7.61 (d, 1H, =CH-Ar, J = 16.2 
Hz), 8.82 (bs, 1H, CONH), 9.16 (bs, 1H, NH). 13C-NMR 
(CDCl3, 100 MHz), δ (ppm): 30.57 (CH2), 112.18-148.24 
(26C, CH=CH and Ar-C), 162.21 (C=O), 168.07 (C=N), 
173.22 (CONH). Anal. found: C, 48.49; H, 2.51; N, 9.37%; 




Yield: 67%. m.p. 161-163 °C. IR (KBr) (cm-1): 3448 (NH 
str), 2933, 2858 (CH2 str), 1718 (C=O str), 1612 (C=N str), 
1579 (CH=CH str), 752 (C-Cl str), 578 (C-Br str). 1H-NMR 
(CDCl3, 400 MHz), δ (ppm): 2.84 (s, 6H, N(CH3)2), 3.55 (s, 
2H, CH2), 6.37-8.15 (m, 13H, Ar-H), 6.78 (d, 1H, =CHCO, J 
= 16.4 Hz), 7.59 (d, 1H, =CH-Ar, J = 16.4 Hz), 8.78 (bs, 1H, 
CONH), 9.13 (bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), δ 
(ppm): 30.27 (CH2), 46.64 (N-(CH3)2), 111.92-150.13 (26C, 
CH=CH and Ar-C), 162.14 (C=O), 168.12 (C=N), 173.06 
(CONH). Anal. found: C, 51.67; H, 3.32; N, 9.47%; Calcd. 




Yield: 65 %. m.p. 157-159 °C. IR (KBr) (cm-1): 3453 (NH 
str), 2928, 2850 (CH2 str), 1723 (C=O str), 1615 (C=N str), 
1580 (CH=CH str), 1245, 1103 (C-O-C str), 751, (C-Cl str), 
570 (C-Br str). 1H-NMR (CDCl3, 400 MHz), δ (ppm): 3.52 
(s, 2H, CH2), 3.65 (s, 3H, OCH3), 6.38-8.15 (m, 13H, Ar-H), 
6.82 (d, 1H, =CHCO, J = 16 Hz), 7.63 (d, 1H, =CH-Ar, 
J = 16 Hz), 8.80 (bs, 1H, CONH), 9.18 (bs, 1H, NH). 
13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.64 (CH2), 61.15 
(OCH3), 112.23-156.34 (26C, CH=CH and Ar-C), 162.26 
(C=O), 167.79 (C=N), 173.35 (CONH). Anal. found: C, 
50.92; H, 3.10; N, 7.62 %; Calcd. for C31H22Br2Cl2N4O3, C, 




Yield: 68%. m.p. 173-175°C. IR (KBr) (cm-1): 3442 (NH 
str), 2923, 2849 (CH2 str), 1710 (C=O str), 1609 (C=N str), 
1581 (CH=CH str), 1243, 1108 (C-O-C str), 745 (C-Cl str), 
569 (C-Br str). 1H-NMR (CDCl3, 400 MHz), δ (ppm): 3.51 
(s, 2H, CH2), 3.66 (s, 3H, OCH3), 6.37-8.16 (m, 13H, Ar-H), 
6.80 (d, 1H, =CHCO, J = 16.2 Hz), 7.58 (d, 1H, =CH-Ar, 
J = 16.2 Hz), 8.78 (bs, 1H, CONH), 9.16 (bs, 1H, NH). 
13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.57 (CH2), 59.38 
(OCH3), 111.97-158.29 (26C, CH=CH and Ar-C), 161.97 
(C=O), 167.86 (C=N), 173.16 (CONH). Anal. found: C, 
51.14; H, 3.01; N, 7.67%; Calcd. for C31H22Br2Cl2N4O3, C, 
51.06; H, 3.04; N, 7.68%.




A mixture of 2-[2-(2,6-dichlorophenyl)amino]benzyl-3-
(phenylacrylamido)-6,8-dibromo quinazolin-4(3H)one 
5a (0.01 mol) and hydrazine hydrate (0.01 mol) in 30 ml 
absolute methanol was added few drops of glacial acetic 
acid and refluxed for 8-10 h. After completion of the 
reaction, excess of solvent was distilled off; the separated 
solid was filtered, washed with water, and recrystallized 
from methanol. Similarly other pyrazolyl derivatives 6b-m 
were synthesized.




Yield: 58 %. m.p. 133-135 °C. IR (KBr) (cm-1): 3443 (NH 
str), 2924, 2853 (CH2 str), 1727 (C=O str), 1612 (C=N 
str), 747 (C-Cl str), 575 (C-Br str). 1H-NMR (CDCl3, 400 
MHz), δ (ppm): 3.04 (dd, 1H, Ha, Ja,b = 17.4 Hz, Jax = 5.5 
Hz), 3.47 (dd, 1H, Hb, Jba = 17.4 Hz, Jbx = 12 Hz), 3.54 
(s, 2H, CH2), 5.49 (dd, 1H, Hx, Jxb = 12 Hz, Jxa = 5.5 Hz), 
6.38-8.15 (m, 15H, NH and Ar-H), 8.35 (bs, 1H, NH), 9.17 
(bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.46 
(CH2), 36.42 (CH2 of pyrazole), 55.57 (CH of pyrazole), 
112.43-148.57 (24C, Ar-C), 161.17 (C=N of pyrazole), 
162.15 (C=O), 168.34 (C=N). Anal. found: C, 50.46; H, 
3.08; N, 11.72 %; Calcd. for C30H22Br2Cl2N6O, C, 50.52; 




Yield: 62 %. m.p. 149-151 °C. IR (KBr) (cm-1): 3543 (OH 
str), 3440 (NH str), 2927, 2853 (CH2 str), 1732 (C=O str), 
1607 (C=N str), 755 (C-Cl str), 578 (C-Br str). 1H-NMR 
(CDCl3, 400 MHz), δ (ppm): 3.02 (dd, 1H, Ha, Ja,b = 17.4 
Hz, Jax = 5.5 Hz), 3.45 (dd, 1H, Hb, Jba = 17.4 Hz, Jbx = 11.9 
Hz), 3.56 (s, 2H, CH2), 5.48 (dd, 1H, Hx, Jxb = 11.9 Hz, Jxa 
= 5.5 Hz), 6.37-8.14 (m, 14H, NH and Ar-H), 8.42 (bs, 1H, 
NH), 9.15 (bs, 1H, NH), 10.35 (bs, 1H, OH). 13C-NMR 
(CDCl3, 100 MHz), δ (ppm): 30.60 (CH2), 35.41 (CH2 of 
pyrazole), 55.65 (CH of pyrazole), 112.19-155.63 (24C, 
Ar-C), 161.21 (C=N of pyrazole), 161.94 (C=O), 168.29 
(C=N). Anal. found: C, 49.38; H, 3.03; N, 11.54 %; Calcd. 




Yield: 67 %. m.p. 162-163 °C. IR (KBr) (cm-1): 3540 (OH 
str), 3453 (NH str), 2928, 2854 (CH2 str), 1730 (C=O str), 
1609 (C=N str), 750 (C-Cl str), 578 (C-Br str). 1H-NMR 
(CDCl3, 400 MHz), δ (ppm): 3.05 (dd, 1H, Ha, Ja,b = 17.6 
Hz, Jax = 5.4 Hz), 3.46 (dd, 1H, Hb, Jba = 17.6 Hz, Jbx = 12 
Hz), 3.53 (s, 2H, CH2), 5.48 (dd, 1H, Hx, Jxb = 12 Hz, Jxa 
= 5.4 Hz), 5.59 (bs, 1H, OH), 6.37-8.15 (m, 14H, NH and 
Ar-H), 8.37 (bs, 1H, NH), 9.14 (bs, 1H, NH). 13C-NMR 
(CDCl3, 100 MHz), δ (ppm): 30.48 (CH2), 36.53 (CH2 of 
pyrazole), 54.98 (CH of pyrazole), 112.23-159.33 (24C, 
Ar-C), 161.13 (C=N of pyrazole), 162.26 (C=O), 168.09 
(C=N). Anal. found: C, 49.33; H, 3.08; N, 11.55 %; Calcd. 




Yield: 63 %. m.p. 177-179 °C. IR (KBr) (cm-1): 3550 (OH 
str), 3448 (NH str), 2931, 2852 (CH2 str), 1725 (C=O str), 
1608 (C=N str), 743 (C-Cl str), 583 (C-Br str). 1H-NMR 
(CDCl3, 400 MHz), δ (ppm): 3.07 (dd, 1H, Ha, Ja,b = 
17.4 Hz, Jax = 5.4 Hz), 3.49 (dd, 1H, Hb, Jba = 17.4 Hz, 
Jbx = 11.8 Hz), 3.56 (s, 2H, CH2), 5.46 (dd, 1H, Hx, Jxb 
= 11.8 Hz, Jxa = 5.4 Hz), 5.58 (bs, 1H, OH), 6.37-8.12 
(m, 14H, NH and Ar-H), 8.40 (bs, 1H, NH), 9.17 (bs, 
1H, NH). 13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.39 
(CH2), 36.51 (CH2 of pyrazole), 55.62 (CH of pyrazole), 
112.18-157.38 (24C, Ar-C), 161.34 (C=N of pyrazole), 
162.04 (C=O), 167.97 (C=N). Anal. found: C, 49.46; H, 
3.05; N, 11.48 %; Calcd. for C30H22Br2Cl2N6O2, C, 49.41; 




Yield: 59 %. m.p. 143-145 °C. IR (KBr) (cm-1): 3442 (NH 
str), 2924, 2847 (CH2 str), 1720 (C=O str), 1611 (C=N 
str), 741 (C-Cl str), 585 (C-Br str). 1H-NMR (CDCl3, 400 
MHz), δ (ppm): 3.02 (dd, 1H, Ha, Ja,b = 17.2 Hz, Jax = 5.5 
Hz), 3.46 (dd, 1H, Hb, Jba = 17.2 Hz, Jbx = 12 Hz), 3.54 
(s, 2H, CH2), 5.48 (dd, 1H, Hx, Jxb = 12 Hz, Jxa = 5.5 Hz), 
6.38-8.14 (m, 14H, NH and Ar-H), 8.38 (bs, 1H, NH), 9.15 
(bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.32 
(CH2), 36.46 (CH2 of pyrazole), 55.56 (CH of pyrazole), 
112.03-148.57 (24C, Ar-C), 161.25 (C=N of pyrazole), 
162.13 (C=O), 168.10 (C=N). Anal. found: C, 48.12; H, 
2.81; N, 11.25 %; Calcd. for C30H21Br2Cl3N6O, C, 48.19; 




Yield: 67 %. m.p. 151-153 °C. IR (KBr) (cm-1): 3447 (NH 
str), 2926, 2850 (CH2 str), 1723 (C=O str), 1613 (C=N 
str), 749 (C-Cl str), 579 (C-Br str). 1H-NMR (CDCl3, 400 
MHz), δ (ppm): 3.04 (dd, 1H, Ha, Ja,b = 17.4 Hz, Jax = 
5.5 Hz), 3.47 (dd, 1H, Hb, Jba = 17.4 Hz, Jbx = 11.8 Hz), 
3.52 (s, 2H, CH2), 5.46 (dd, 1H, Hx, Jxb = 11.8 Hz, Jxa = 
5.5 Hz), 6.38-8.15 (m, 14H, NH and Ar-H), 8.40 (bs, 1H, 
NH), 9.13 (bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), δ 
(ppm): 30.24 (CH2), 36.56 (CH2 of pyrazole), 55.63 (CH 
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of pyrazole), 112.17-148.66 (24C, Ar-C), 161.20 (C=N of 
pyrazole), 162.18 (C=O), 168.21 (C=N). Anal. found: C, 
48.26; H, 2.79; N, 11.22 %; Calcd. for C30H21Br2Cl3N6O, 




Yield: 63 %. m.p. 166-168 °C. IR (KBr) (cm-1): 3440 (NH 
str), 2921, 2848 (CH2 str), 1719 (C=O str), 1608 (C=N 
str), 743 (C-Cl str), 575 (C-Br str). 1H-NMR (CDCl3, 400 
MHz), δ (ppm): 3.06 (dd, 1H, Ha, Ja,b = 17.5 Hz, Jax = 
5.4 Hz), 3.49 (dd, 1H, Hb, Jba = 17.5 Hz, Jbx = 11.9 Hz), 
3.54 (s, 2H, CH2), 5.48 (dd, 1H, Hx, Jxb = 11.9 Hz, Jxa = 
5.4 Hz), 6.37-8.16 (m, 14H, NH and Ar-H), 8.37 (bs, 1H, 
NH), 9.14 (bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), δ 
(ppm): 30.38 (CH2), 36.42 (CH2 of pyrazole), 55.53 (CH 
of pyrazole), 111.98-148.57 (24C, Ar-C), 161.23 (C=N of 
pyrazole), 162.29 (C=O), 168.36 (C=N). Anal. found: C, 
48.08; H, 2.80; N, 11.28 %; Calcd. for C30H21Br2Cl3N6O, 




Yield: 69 %. m.p. 169-171 °C. IR (KBr) (cm-1): 3450 (NH 
str), 2928, 2852 (CH2 str), 1725 (C=O str), 1612 (C=N 
str), 1548, 1363 (NO2 str), 754 (C-Cl str), 572 (C-Br str). 
1H-NMR (CDCl3, 400 MHz), δ (ppm): 3.04 (dd, 1H, Ha, Ja,b 
= 17.6 Hz, Jax = 5.5 Hz), 3.47 (dd, 1H, Hb, Jba = 17.6 Hz, Jbx 
= 12 Hz), 3.52 (s, 2H, CH2), 5.46 (dd, 1H, Hx, Jxb = 12 Hz, 
Jxa = 5.5 Hz), 6.39-8.16 (m, 14H, NH and Ar-H), 8.41 (bs, 
1H, NH), 9.15 (bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), 
δ (ppm): 30.21 (CH2), 36.59 (CH2 of pyrazole), 55.68 (CH 
of pyrazole), 112.10-150.38 (24C, Ar-C), 161.12 (C=N of 
pyrazole), 162.35 (C=O), 168.19 (C=N). Anal. found: C, 
47.43; H, 2.75; N, 12.89 %; Calcd. for C30H21Br2Cl2N7O3, 




Yield: 61 %. m.p. 187-189 °C. IR (KBr) (cm-1): 3455 
(NH str), 2930, 2855 (CH2 str), 1727 (C=O str), 1615 
(C=N str), 1542, 1360 (NO2 str), 750 (C-Cl str), 577 
(C-Br str). 1H-NMR (CDCl3, 400 MHz), δ (ppm): 3.02 
(dd, 1H, Ha, Ja,b = 17.5 Hz, Jax = 5.4 Hz), 3.45 (dd, 1H, 
Hb, Jba = 17.5 Hz, Jbx = 11.8 Hz), 3.53 (s, 2H, CH2), 
5.47 (dd, 1H, Hx, Jxb = 11.8 Hz, Jxa = 5.4 Hz), 6.38-8.39 
(m, 14H, NH and Ar-H), 8.42 (bs, 1H, NH), 9.17 (bs, 
1H, NH). 13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.27 
(CH2), 36.52 (CH2 of pyrazole), 55.65 (CH of pyrazole), 
112.13-150.46 (24C, Ar-C), 161.05 (C=N of pyrazole), 
162.23 (C=O), 168.14 (C=N). Anal. found: C, 47.45; H, 
2.76; N, 12.92 %; Calcd. for C30H21Br2Cl2N7O3, C, 47.52; 




Yield: 63 %. m.p. 198-199 °C. IR (KBr) (cm-1): 3441 (NH 
str), 2925, 2852 (CH2 str), 1729 (C=O str), 1611 (C=N 
str), 1540, 1363 (NO2 str), 754 (C-Cl str), 587 (C-Br str). 
1H-NMR (CDCl3, 400 MHz), δ (ppm): 3.05 (dd, 1H, Ha, Ja,b 
= 17.4 Hz, Jax = 5.4 Hz), 3.48 (dd, 1H, Hb, Jba = 17.4 Hz, Jbx 
= 12 Hz), 3.57 (s, 2H, CH2), 5.50 (dd, 1H, Hx, Jxb = 12 Hz, 
Jxa = 5.4 Hz), 6.37-8.15 (m, 14H, NH and Ar-H), 8.40 (bs, 
1H, NH), 9.15 (bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), 
δ (ppm): 30.53 (CH2), 36.47 (CH2 of pyrazole), 55.70 (CH 
of pyrazole), 112.24-148.39 (24C, Ar-C), 161.17 (C=N of 
pyrazole), 162.34 (C=O), 168.18 (C=N). Anal. found: C, 
47.40; H, 2.80; N, 12.85 %; Calcd. for C30H21Br2Cl2N7O3, 




Yield: 60 %. m.p. 157-159 °C. IR (KBr) (cm-1): 3454 (NH 
str), 2935, 2857 (CH2 str), 1721 (C=O str), 1616 (C=N 
str), 758 (C-Cl str), 568 (C-Br str). 1H-NMR (CDCl3, 400 
MHz), δ (ppm): 3.06 (dd, 1H, Ha, Ja,b = 17.6 Hz, Jax = 
5.5 Hz), 3.48 (dd, 1H, Hb, Jba = 17.6 Hz, Jbx = 11.9 Hz), 
3.56 (s, 2H, CH2), 5.51 (dd, 1H, Hx, Jxb = 11.9 Hz, Jxa = 
5.5 Hz), 6.38-8.16 (m, 14H, NH and Ar-H), 8.37 (bs, 1H, 
NH), 9.14 (bs, 1H, NH). 13C-NMR (CDCl3, 100 MHz), δ 
(ppm): 30.32 (CH2), 36.38 (CH2 of pyrazole), 55.59 (CH 
of pyrazole), 112.15-150.27 (24C, Ar-C), 161.22 (C=N of 
pyrazole), 162.28 (C=O), 168.24 (C=N). Anal. found: C, 
50.75; H, 3.59; N, 12.98 %; Calcd. for C32H27Br2Cl2N7O, 




Yield: 63 %. m.p. 147-149 °C. IR (KBr) (cm-1): 3440 (NH 
str), 2920, 2846 (CH2 str), 1715 (C=O str), 1606 (C=N 
str), 1248, 1107 (C-O-C str), 759 (C-Cl str), 575 (C-Br str). 
1H-NMR (CDCl3, 400 MHz), δ (ppm): 3.02 (dd, 1H, Ha, 
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Ja,b = 17.4 Hz, Jax = 5.3 Hz), 3.45 (dd, 1H, Hb, Jba = 17.4 
Hz, Jbx = 11.7 Hz), 3.51 (s, 2H, CH2), 3.66 (s, 3H, OCH3), 
5.48 (dd, 1H, Hx, Jxb = 11.7 Hz, Jxa = 5.3 Hz), 6.37-8.15 
(m, 14H, NH and Ar-H), 8.38 (bs, 1H, NH), 9.17 (bs, 1H, 
NH). 13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.51 (CH2), 
36.46 (CH2 of pyrazole), 55.47 (CH of pyrazole), 112.11-
156.26 (24C, Ar-C), 161.12 (C=N of pyrazole), 162.21 
(C=O), 167.94 (C=N). Anal. found: C, 50.02; H, 3.21; N, 





Yield: 69 %. m.p. 165-167 °C. IR (KBr) (cm-1): 3437 (NH 
str), 2918, 2845 (CH2 str), 1718 (C=O str), 1607 (C=N 
str), 1238, 1105 (C-O-C str), 737 (C-Cl str), 562 (C-Br str). 
1H-NMR (CDCl3, 400 MHz), δ (ppm): 3.03 (dd, 1H, Ha, 
Ja,b = 17.5 Hz, Jax = 5.5 Hz), 3.46 (dd, 1H, Hb, Jba = 17.5 
Hz, Jbx = 11.8 Hz), 3.52 (s, 2H, CH2), 3.64 (s, 3H, OCH3), 
5.49 (dd, 1H, Hx, Jxb = 11.8 Hz, Jxa = 5.5 Hz), 6.36-8.16 
(m, 14H, NH and Ar-H), 8.42 (bs, 1H, NH), 9.15 (bs, 1H, 
NH). 13C-NMR (CDCl3, 100 MHz), δ (ppm): 30.64 (CH2), 
36.40 (CH2 of pyrazole), 55.42 (CH of pyrazole), 111.85-
158.32 (24C, Ar-C), 160.97 (C=N of pyrazole), 162.05 
(C=O), 168.02 (C=N). Anal. found: C, 49.96; H, 3.20; N, 
11.24 %; Calcd. for C31H24Br2Cl2N6O2, C, 50.09; H, 3.25; 
N, 11.31 %.
Antimicrobial activity
The in vitro antimicrobial activities of compounds 6a-m 
were carried out by the cup-plate method.[27] Antibacterial 
activity was screened against two gram-positive bacteria 
S. aureus (ATCC 12228) and B. subtilis (ATCC 11778), 
and two gram-negative bacteria E. coli (ATCC 8739) 
and Certium (ATCC 27957), by measuring the zone of 
inhibition on agar plates at two different concentrations 
100 µg/ml and 50 µg/ml. While antifungal activity was 
tested by measuring the zone of inhibition on agar plates 
with two fungal species C. albicans (ATCC 10231) and A. 
niger (ATCC 16404) at two different concentrations 20 
µg/ml and 10 µg/ml. Penicillin-G was used as a standard 
antibacterial agent, whereas fluconazole was used as a 
standard antifungal agent.
RESULTS AND DISCUSSION
The title compounds 2-[2-(2,6-dichlorophenyl)amino]
benzyl-3-(5-substituted phenyl-4,5-dihydro -1H-pyrazol-
3-yl-amino)-6,8-dibromoquinazolin-4(3H)ones 6a-m were 
synthesized according to described process in Scheme 1. 
The structures of all the synthesized compounds were 
elucidated by the elemental analysis as well as IR and NMR 
spectral data. IR spectra showed strong C=O and C=N 
stretching of quinazolinone at around 1720 cm-1 and 1610 
cm-1. The 1H NMR spectra of compounds 6a-m indicated 
that the -CH2 protons of the pyrazoline ring resonated as 
a pair of doublet of doublets (Ha and Hb) due to geminal 
and vicinal coupling. The CH proton appeared as a doublet 
of doublet (Hx) due to vicinal coupling with the two 
magnetically nonequivalent protons of methylene group at 
position 4 of pyrazoline ring. The Ha proton which is cis to 
Hx resonates upfield in the range δ 3.02-3.07 as a doublet 
of doublet while Hb, the other proton which is trans to Hx 
resonates downfield in the range δ 3.45-3.49 as a doublet of 
doublet. The Hx proton which is vicinal to two methylene 
protons (Ha and Hb) resonates as a doublet of doublet 
in the range δ 5.46-5.51. In 13C NMR spectra, signals at 
around δ 36.5, δ 55.5, and δ 161 confirms the presence 
of CH2, CH, and C=N of pyrazoline ring, respectively, 
whereas C=O and C=N signals of quinazolinone ring are 
appear at around δ 162 and δ 168, respectively.
The results of antibacterial activity are shown in Table 
1. Compounds 6a (R = H) and 6h (R = 2-NO2) showed 
good activities against gram-positive bacteria (70.87% and 
63.39% against S. aureus respectively; 73.97% and 69.56% 
against B. subtilis, respectively). The remaining compounds 
showed moderate activities (44.19-55.29%) against gram-
positive bacteria as compared to penicillin-G. Compounds 
containing para-substituted hydroxyl, chloro and methoxy 
groups were found active than ortho- and meta-substituted 
compounds while ortho substituted nitro compound 
showed good activity than meta- and para-substituted nitro 
compounds against gram-positive bacteria. Compounds 
6h (R = 2-NO2) and 6i (R = 3-NO2) exhibited good 
activities against gram-negative bacteria (65.04% and 74% 
against E. coli, respectively; 68.97% and 78.63% against 
Certium, respectively). The remaining compounds showed 
moderate activities (37.98-58.63%) against gram-negative 
bacteria as compared to penicillin-G. Meta-substituted 
hydroxyl and nitro compounds possessed good activity 
against gram-negative bacteria as compared to ortho- and 
para-substituted compounds. Whereas ortho-substituted 
chloro compound was found good as compared to meta 
and para, and methoxy group containing compounds share 
an equal activity against gram-negative bacteria E. coli. On 
the other hand, ortho-substituted methoxy compound was 
found good than para-substituted compound and meta-
substituted chloro compound showed lower activity as 
compared to ortho- and para-substituted chloro compound 
against gram-negative bacteria Certium. Furthermore, 
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compound 6h (R = 2-NO2) was active against all 
gram positive as well as gram-negative bacteria, while 
compound 6a (R = H) was active against both gram-
positive bacteria and compound 6i (R = 3-NO2) was active 
against both gram-negative bacteria. Also, compound 6l 
(R = 2-OCH3) displayed good activity (61.15 %) against 
gram-negative bacteria Certium. In addition compounds 
containing dimethylamino group exhibited quite low 
activity than others against gram-positive as well as gram-
negative bacteria.
The results of antifungal activity are shown in Table 
2. Compounds 6d (R = 4-OH), 6e (R = 2-Cl), 6f (R = 
3-Cl), 6g (R = 4-Cl), and 6h (R = 2-NO2) exhibited very 
good activities (61.84-84.70 %) against C. albicans while 
compounds 6e (R = 2-Cl), 6f (R = 3-Cl), and 6g (R = 
4-Cl) possessed very good activities (63.41-78.57 %) 
against A. niger as compared to standard drug fluconazole. 
The remaining compounds showed moderate activities. 
Compounds 6e (R = 2-Cl) and 6g (R = 4-Cl) exhibited 
pronounced activities (84.70 % and 80.77 %) against C. 
albicans among the series. Ortho-substituted chloro and 
nitro compounds showed good activity as compared to 
meta- and para-substituted compounds against both C. 
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Table 1: Antibacterial activity of compounds 6a-m
Compound R Zone of inhibition (mm)
S. aureus ATCC 12228 B. subtilis ATCC 11778 E. coli ATCC 8739 Certium ATCC 27957
CH CL Pot. % CH CL Pot. % CH CL Pot. % CH CL Pot. %
6a H 21 17 70.87 20 16 73.97 12 10 40.08 11 9 41.85
6b 2-OH 15 12 52.83 14 12 50.10 16 13 52.45 15 13 52.40
6c 3-OH 13 10 48.23 12 10 44.19 17 14 55.02 16 13 58.22
6d 4-OH 15 12 52.83 15 13 53.35 16 13 52.45 15 12 55.43
6e 2-Cl 13 10 48.23 12 10 44.19 14 12 44.63 13 11 46.83
6f 3-Cl 13 10 48.23 12 10 44.19 12 10 40.08 11 9 41.85
6g 4-Cl 14 11 50.47 13 11 47.05 13 11 42.30 13 11 46.83
6h 2-NO2 19 16 63.39 19 16 69.56 20 16 65.04 19 15 68.97
6i 3-NO2 15 12 52.83 14 12 50.10 23 19 74.00 22 18 78.63
6j 4-NO2 16 13 55.29 15 13 53.35 17 14 55.02 16 13 58.22
6k 4-N(CH3)2 13 10 48.23 12 10 44.19 11 9 37.98 10 8 39.56
6l 2-OCH3 14 11 50.47 13 11 47.05 18 15 57.71 17 14 61.15
6m 4-OCH3 15 12 52.83 14 12 50.10 18 15 57.71 17 15 58.63
Penicillin 30 25 100 27 21 100 31 25 100 28 23 100
CH = zone of inhibition at 100 µg/ml; CL = zone of inhibition at 50 µg/ml; Pot. = potency in %
Table 2: Antifungal activity of compounds 6a-m
Compound R Zone of inhibition (mm)
C. albicans  ATCC 10231 A. niger ATCC 16404
CH CL Pot. % CH CL Pot. %
6a H 15 12 58.63 15 13 51.52
6b 2-OH 10 8 41.28 9 7 35.88
6c 3-OH 7 0 49.07 6 0 41.30
6d 4-OH 9 7 68.84 9 7 35.88
6e 2-Cl 22 18 84.70 22 18 78.57
6f 3-Cl 19 16 72.59 18 15 63.41
6g 4-Cl 21 17 80.77 20 16 71.35
6h 2-NO2 16 13 61.84 15 13 51.52
6i 3-NO2 13 11 49.57 12 10 43.00
6j 4-NO2 15 13 56.01 14 12 48.51
6k 4-N(CH3)2 15 13 56.01 15 13 51.52
6l 2-OCH3 7 0 49.07 6 0 41.30
6m 4-OCH3 7 0 49.07 6 0 41.30
Fluconazole 26 21 100 28 22 100
CH = zone of inhibition at 20 µg/ml; CL = zone of inhibition at 10 µg/ml; Pot. = potency in %
albicans and A. niger. On the other hand, para-substituted 
hydroxyl compound was found good against C. albicans as 
compared to ortho and meta, while meta-substituted hydroxyl 
compound possessed higher activity against A. niger than 
ortho- and para-substituted compounds. Both ortho and 
para-substituted methoxy group containing compounds 
exhibited same activity against C. albicans and A. niger.
CONCLUSIONS
All the compounds showed satisfactory elemental as well as 
IR and NMR spectral results.  Compounds bearing 2-nitro 
group showed promising activity against all bacterial species 
while chloro group-containing compounds were found 
active against both fungal species. All this findings give 
ideas to improve antimicrobial activity for further studies.
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